Welcome to our dedicated page for Zynex news (Ticker: ZYXI), a resource for investors and traders seeking the latest updates and insights on Zynex stock.
Zynex, Inc. (ZYXI) is a Nevada-incorporated medical technology company that develops, manufactures, markets, and sells non-invasive medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. The ZYXI news feed on Stock Titan aggregates company-issued press releases and other coverage that reflect both its operating activities and its financial and regulatory developments.
News about Zynex often highlights its medical device portfolio and corporate events. Company announcements describe its efforts to provide devices that support pain management and rehabilitation and to advance patient monitoring technologies, including multi-parameter and laser-based pulse oximetry. Updates have included submissions of products such as the NiCO laser pulse oximeter for FDA 510(k) review and subsequent strategic decisions to seek commercialization partners through its Zynex Monitoring Solutions subsidiary.
Investors following ZYXI news will also see disclosures related to the company’s financial performance, liquidity, and capital structure. Recent press releases and SEC-related announcements have discussed revenue trends, the impact of a temporary payment suspension from Tricare, restructuring measures, and the company’s evaluation of strategic alternatives with the assistance of external financial advisors and a special committee of the board.
Regulatory and capital markets developments are another key theme in Zynex news. In December 2025, Zynex announced that it had voluntarily entered into Chapter 11 court-supervised financial restructuring and later reported that Nasdaq had determined to delist its common stock as a result of the Chapter 11 cases. These items, along with leadership changes and board appointments, appear in the news flow and provide context on governance and oversight.
By reviewing the ZYXI news page, readers can track company communications on product strategy, restructuring progress, leadership changes, and listing status. This consolidated view helps users understand how Zynex’s medical technology focus intersects with its financial and regulatory path over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Zynex, a medical technology company listed under Nasdaq: ZYXI, has announced it will report its first-quarter financial results for 2023 on April 27, 2023. The report will include insights into their non-invasive medical devices for pain management and rehabilitation. Management will discuss the results during a conference call and webcast scheduled for 2:15 PM MT / 4:15 PM ET. Interested participants can register via the provided link or dial in.
Founded in 1996, Zynex specializes in developing and selling medical devices used in hospitals and patient care. The company emphasizes its forward-looking statements regarding future conditions and the inherent uncertainties involved.
Zynex, Inc. (NASDAQ: ZYXI) reported preliminary results for Q1 2023, showcasing significant growth in the pain management division. Orders reached a record high, up 61% from Q1 2022. Revenue estimates for the quarter are projected between $39.0 million and $41.0 million, reflecting a 29% increase from the previous year. The company maintains its full-year guidance, forecasting revenue of $180 million to $200 million and earnings per share between $0.40 and $0.50. Seasonal trends in the healthcare industry affect Q1 revenues, aligning with historical patterns. CEO Thomas Sandgaard emphasized strong sales momentum and growth potential as the company expands its market presence.
Zynex, Inc. (NASDAQ: ZYXI) has been ranked 191 out of 500 on The Financial Times' fourth annual list of The Americas' Fastest Growing Companies 2023. This recognition highlights Zynex's consistent revenue growth, achieving a remarkable 308% increase in revenue and a compound annual growth rate (CAGR) of 60% between 2018 and 2021. CEO Thomas Sandgaard emphasized that this accolade reflects the company's ongoing performance along with 24 other publicly traded companies in the Healthcare & Life Sciences sector. Zynex specializes in non-invasive medical devices for pain management, rehabilitation, and patient monitoring.
Summary not available.
Zynex, Inc. (Nasdaq: ZYXI) reported strong financial results for Q4 and full year 2022, highlighting a 21% revenue growth year-over-year to $48.8 million for Q4, with orders up 48%. Full year revenue also increased 21%, totaling $158.2 million, while net income reached $17.0 million, reflecting profitability for the seventh consecutive year. The company's working capital stood at $48.5 million, with cash on hand at $20.1 million. For 2023, Zynex projects revenue between $180 million and $200 million, anticipating first quarter revenue of $39-41 million, influenced by seasonal trends.
Zynex, Inc. (NASDAQ: ZYXI) announced the rescheduled release date for its fourth quarter and full-year 2022 financial results, now set for March 13, 2023. The company specializes in non-invasive medical devices for pain management and rehabilitation. A conference call will occur at 6:30 a.m. MT / 8:30 a.m. ET to discuss these results and provide a corporate update. Zynex has a longstanding commitment to innovation in medical technology and is focused on delivering advanced solutions for patient care.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
